Todd Hembrough

Durham VA Medical Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index4.5kcitations248works0.22yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(62), Lung Cancer Treatments and Mutations(40), Cancer Immunotherapy and Biomarkers(36), Cancer, Hypoxia, and Metabolism(34), Sarcoma Diagnosis and Treatment(29)

Publications247 total

Abstract P1-03-23: Identification of Stage 1 Breast Cancer Biomarkers Using Extracellular Vesicle Proteomics and Machine Learning
Clinical Cancer Research·2025
Detection of early-stage colorectal cancer using multiplexed extracellular vesicle proteomic biomarkers.
Journal of Clinical Oncology·2025
Abstract 1891: Identification of highly accurate early-stage specific NSCLC biomarkers from extracellular vesicles identifies immune response and metabolic biomarkers associated with cancer
Cancer Research·2025· 2 cited
Abstract 1914: Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers
Cancer Research·2025
Abstract 3032: Selective pharmacological activation of the mitochondrial protease OMA1 inhibits tumor growth and induces regression in tumors expressing low levels of FAM210B
Cancer Research·2025
Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers.
Journal of Clinical Oncology·2025
Abstract PR013: Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers
Clinical Cancer Research·2024
Abstract A063: Highly accurate detection of early-stage colorectal cancer using tumor and immune extracellular vesicles biomarkers
Clinical Cancer Research·2024
Abstract 3746: Identification of cancer specific extracellular vesical biomarkers to aid in diagnosis of cancer
Cancer Research·2024
Supplementary Table S1 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S3 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Figures from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S2 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S1 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Data from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Figures from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Data from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S5 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S3 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
Supplementary Table S2 from Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
2023Open Access
page 1 of 13Next →

Frequent Co-authors

Franco Cecchi(25), Daniel V.T. Catenacci(10), Sheeno Thyparambil(10), Jon Burrows(8), Wei‐Li Liao(7), Sarit Schwartz(6), Les Henderson(6), Emily O’Day(6), Yuan Tian(6), Wei-Li Liao(5), David B. Krizman(5), Bob T. Li(4), Michael Offin(4), Charles M. Rudin(4), Maurizio Scaltriti(4), Maria E. Arcila(4), Mark G. Kris(4), Steven L. Gonias(4), John Hart(4), Shu‐Yuan Xiao(4)